ArisGlobal Blogs

Individual Case Safety Reports, or ICSRs, are a large part of the safety and pharmacovigilance lifecycle. From reporting…

As part of our executive series, the ArisGlobal marketing…

Christina Johnston, Associate Director of Product Management for Regulatory at ArisGlobal, recently presented “AI Enhanced RIMS: What…

On June 9th, 2020 ArisGlobal held a webinar titled “Pharmacovigilance and Digital Transformation: Stepping…

On June 9, 2020 ArisGlobal held a webinar titled “Pharmacovigilance and Digital Transformation: Stepping into the Technology-Driven…

On June 16th, 2020, ArisGlobal participated in the 2020 DIA Annual Meeting, where Sondra Pepe, Senior…

As evident from our second polling question, ”How far along the road would you say you are for a ‘new’ technological revolution,” the journey to capitalize on the next industrial revolution is just beginning for most participants

As evident from our second polling question, ”How far along the road would you say you are for a ‘new’ technological revolution,” the journey to capitalize on the next industrial revolution is just beginning for most participants

Automation technologies are having a major impact on performance and productivity across industries. In regulatory, these technologies also have the potential to reshape many activities across regulatory, leading to significant productivity gains. While there’s a lot of talk about how automation technologies will create new roles with exciting opportunities, the most powerful impact will be on the data quality and the efficiency with which manual tasks will be accomplished.

“The most competitive pharma companies in the coming decade will be masters of data and digital technologies.” So begins the June 2017 industry brief, “Reinventing the Role of Medical Affairs,” by Bain & Company.